ArticleFrontiers in medicine2026
Case Report: Tocilizumab as time-limited induction therapy enabling steroid withdrawal and conventional maintenance in refractory cutaneous polyarteritis nodosa.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous polyarteritis nodosa (CPAN) is a chronic, relapsing vasculitis frequently associated with glucocorticoid dependence and the absence of standardized treatment algorithms. Therapeutic decisions are largely empirical and management of refractory disease remains challenging. Case presentation: We report a patient with refractory CPAN and persistent steroid dependence despite corticosteroids and conventional immunosuppressive therapies. A deliberately planned, time-limited induction strategy with tocilizumab (TCZ) was implemented to achieve rapid disease control and enable steroid withdrawal, followed by maintenance with mycophenolate mofetil (MMF). Results: TCZ led to rapid clinical remission after two infusions, allowing progressive steroid tapering and discontinuation. After six doses, TCZ was stopped and MMF was introduced as maintenance therapy. The patient remains lesion-free at the time of manuscript submission. Conclusion: A time-limited IL-6 blockade strategy may allow rapid steroid withdrawal and facilitate transition to conventional maintenance in refractory CPAN. This approach may reduce cumulative exposure to both glucocorticoids and biologic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.